Delayed Embryo Transfer in Poor Responders

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT02431689
Collaborator
Nile Ivf Center, Cairo, Egypt (Other), Kamal Shaeer center of infertility (Other)
400
3
2
37
133.3
3.6

Study Details

Study Description

Brief Summary

Poor ovarian response indicates inadequate ovarian response to ovarian stimulation. In the current study the investigators will attempt to compare antagonist and short protocols regarding oocyte as well as embryo quantity and quality. Frozen embryo transfer will be performed in order to abolish iatrogenic effect of stimulation drugs on implantation. Still implantation and pregnancy rates are considered secondary outcomes.

Condition or Disease Intervention/Treatment Phase
  • Procedure: IVF/ICSI
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Antagonist and Short Protocols in Invitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) Cycles With Delayed Embryo Transfer in Poor Ovarian Response
Actual Study Start Date :
Apr 1, 2015
Actual Primary Completion Date :
May 1, 2018
Actual Study Completion Date :
May 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Antagonist

Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter. Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred.

Procedure: IVF/ICSI
controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.

Active Comparator: Short

Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter. Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred.

Procedure: IVF/ICSI
controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.

Outcome Measures

Primary Outcome Measures

  1. Number of Metaphase II (MII) oocytes [9-14 days from stimulation]

    Number of MII oocytes collected from each patient on the day of ovum pickup (OPU)

  2. Number of good embryos [3-5 days after ovum pickup]

    the number of good quality embryos obtained from each patient

Secondary Outcome Measures

  1. chemical pregnancy rate [14 days after embryo transfer]

    positive serum Beta HCG 14 days after embryo transfer

  2. clinical pregnancy rate [5 weeks after embryo transfer]

    the detection of intrauterine gestational sac with positive pulsations

  3. Implantation rate [5 weeks after embryo transfer]

    the ratio between the number of embryos transferred and the number of sacs

  4. Early miscarriage rate [3 months]

    Pregnancy loss in the first 12 weeks gestation

  5. Ongoing pregnancy rate [3 months]

    Pregnancy ongoing beyond 12 weeks gestation

  6. Live birth rate [9 months]

    Pregnancy ending with a live birth

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient selection is based on the ESHRE consensus group 2011 definition of poor ovarian response (POR) (Bologna criteria):

  • At least two of the following three features must be present:

  1. Advanced maternal age (≥40 years) or any other risk factor for POR;

  2. A previous POR (≤3 oocytes with a conventional stimulation protocol);

  3. An abnormal ovarian reserve test (i.e. Antral follicle count (AFC) <5-7 follicles or Antimullerian hormone (AMH) <0.5-1.1 ng/ml).

Two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal Ovarian reserve test (ORT). By definition, the term POR refers to the ovarian response and, therefore, one stimulated cycle is considered essential for the diagnosis of POR. However, patients over 40 years of age with an abnormal ORT may be classified as poor responders since both advanced age and an abnormal ORT may indicate reduced ovarian reserve and act as a surrogate of ovarian stimulation cycle. In this case, the patients should be more properly defined as expected PORs.

Exclusion Criteria:
  • Women with endometriosis, endocrinal problems, uterine abnormalities as well as male azospermia.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini) Cairo Egypt 12311
2 Kamal Shaeer center of infertility Giza Egypt 12411
3 Nile IVF center Giza Egypt 12411

Sponsors and Collaborators

  • Cairo University
  • Nile Ivf Center, Cairo, Egypt
  • Kamal Shaeer center of infertility

Investigators

  • Study Director: Iman K Shaeer, MD, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yasmin Ahmed Bassiouny, Dr, Cairo University
ClinicalTrials.gov Identifier:
NCT02431689
Other Study ID Numbers:
  • 32015
First Posted:
May 1, 2015
Last Update Posted:
May 15, 2018
Last Verified:
May 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 15, 2018